TABLE: Mapping the Genome Companies
Pharmaceutical giants and biotech startups are mining the treasures in the
human genome. Some key players:
HUMAN GENOME Sequencing almost all human genes, then hopes to
SCIENCES develop drugs and diagnostics, mostly with partners.
SMITHKLINE Invested $125 million in HGS to use its sequences to
BEECHAM create new products.
INCYTE Sequencing cDNA from many different tissues to find
PHARMACEUTICAL interesting genes. Is selling access to its data.
PFIZER Paid InCyte $25 million for access to database.
UPJOHN Signed $20 million deal with InCyte for gene data.
BRISTOL-MYERS Invested in SEQ and Cadus to develop new
SQUIBB sequencing technology and drug screens.
MILLENNIUM Searching for specific genes that cause obesity,
diabetes, asthma, atherosclerosis, and cancer.
HOFFMANN- Signed $70 million deal with Millennium.
MERCK Paid Washington University to sequence
200,000 gene fragments. Makes data public.
SEQUANA Searches family histories and HMO data for genes
THERAPEUTICS that cause hypertension, asthma, and obesity.
AMGEN Sequencing genes to find new drug targets.
TAKEDA Uses SmithKline and HGS data to develop drugs.
DATA: BUSINESS WEEK